[go: up one dir, main page]

SI2299977T1 - Liposomi za dostavo zdravil in postopki za njihovo pripravo - Google Patents

Liposomi za dostavo zdravil in postopki za njihovo pripravo

Info

Publication number
SI2299977T1
SI2299977T1 SI200930343T SI200930343T SI2299977T1 SI 2299977 T1 SI2299977 T1 SI 2299977T1 SI 200930343 T SI200930343 T SI 200930343T SI 200930343 T SI200930343 T SI 200930343T SI 2299977 T1 SI2299977 T1 SI 2299977T1
Authority
SI
Slovenia
Prior art keywords
liposomes
preparation
methods
drug delivery
drug
Prior art date
Application number
SI200930343T
Other languages
English (en)
Inventor
Anders Falk Vikbjerg
Sune Allan Petersen
Fredrik Melander
Jonas Rosager Henriksen
Kent Jorgensen
Original Assignee
Liplasome Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma Aps filed Critical Liplasome Pharma Aps
Publication of SI2299977T1 publication Critical patent/SI2299977T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200930343T 2008-05-23 2009-05-25 Liposomi za dostavo zdravil in postopki za njihovo pripravo SI2299977T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200800717 2008-05-23
EP08014793A EP2123258A1 (en) 2008-05-23 2008-08-20 Liposomes for drug delivery
EP09749940A EP2299977B1 (en) 2008-05-23 2009-05-25 Liposomes for drug delivery and methods for preparation thereof
PCT/EP2009/056297 WO2009141450A2 (en) 2008-05-23 2009-05-25 Liposomes for drug delivery and methods for preparation thereof

Publications (1)

Publication Number Publication Date
SI2299977T1 true SI2299977T1 (sl) 2012-11-30

Family

ID=40221427

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200930343T SI2299977T1 (sl) 2008-05-23 2009-05-25 Liposomi za dostavo zdravil in postopki za njihovo pripravo

Country Status (14)

Country Link
US (2) US20120009243A1 (sl)
EP (2) EP2123258A1 (sl)
JP (1) JP5767580B2 (sl)
CN (1) CN102065840B (sl)
AU (1) AU2009248673B2 (sl)
CA (1) CA2725529C (sl)
CY (1) CY1115325T1 (sl)
DK (1) DK2299977T3 (sl)
ES (1) ES2393170T3 (sl)
HR (1) HRP20120776T1 (sl)
PL (1) PL2299977T3 (sl)
PT (1) PT2299977E (sl)
SI (1) SI2299977T1 (sl)
WO (1) WO2009141450A2 (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) * 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
US8747891B2 (en) * 2011-05-10 2014-06-10 The Penn State Research Foundation Ceramide anionic liposome compositions
CN102579350B (zh) * 2012-03-02 2013-04-24 海南灵康制药有限公司 右旋布洛芬脂质体固体制剂
ES2733061T3 (es) * 2012-08-10 2019-11-27 Taiho Pharmaceutical Co Ltd Dispersión acuosa de liposomas encapsulantes de oxaliplatino estable y método para estabilización de la misma
MA37931A1 (fr) * 2012-08-13 2016-07-29 Teni Boulikas Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite
CN103169659A (zh) * 2012-11-23 2013-06-26 杭州师范大学 一种奥沙利铂长循环脂质体及其应用
CN110478481A (zh) * 2013-03-13 2019-11-22 比奥阿赛斯技术有限公司 p97片段及其应用
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
CN104758250B (zh) * 2015-03-04 2021-06-01 王海龙 一种紫杉醇脂质体及其制备方法和用途
WO2016199430A1 (ja) * 2015-06-10 2016-12-15 学校法人帝京大学 セラノスティクス用のバブル製剤（ｔｂ）及びその使用方法
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
EP3612229A4 (en) 2017-04-19 2020-04-29 Mayo Foundation for Medical Education and Research MIX OF KETAMINE AND PROPOFOL
US11590079B2 (en) 2018-01-18 2023-02-28 EndoProtech, Inc. Treating microvascular dysfunction
AU2019200325A1 (en) * 2018-01-31 2019-08-15 Liplasome Pharma Aps Methods for treating cancer and predicting drug responsiveness in cancer patients
CN110522728B (zh) * 2019-10-11 2022-03-15 上海市同仁医院 一种介孔二氧化硅纳米递药系统、制备方法及其应用
US20230285292A1 (en) * 2020-06-23 2023-09-14 The Trustees Of The University Of Pennsylvania Compositions and methods of using a pla2-responsive drug delivery system
WO2025072609A1 (en) * 2023-09-30 2025-04-03 Fordoz Pharma Corp. Liposomal amphotericin b compositions and methods

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
IL93996A0 (en) * 1989-04-04 1991-01-31 Alcon Lab Inc Pharmaceutical composition containing a liposome
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US6417326B1 (en) * 1996-04-11 2002-07-09 The University Of British Columbia Fusogenic liposomes
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
AU1656799A (en) 1997-12-12 1999-07-05 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
US6911306B1 (en) 1999-10-18 2005-06-28 Emory University TMS1 compositions and methods of use
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CA2399821A1 (en) * 2000-02-10 2001-08-16 Liplasome Pharma A/S Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof
JP2004528025A (ja) * 2001-02-21 2004-09-16 サーロメッド・インコーポレーテッド 修飾されたアネキシン蛋白質及び血栓症を防ぐための方法
US20030026831A1 (en) * 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
AU2002340669A1 (en) 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions with enhanced blood stability
AU2002340670A1 (en) * 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
US20040018525A1 (en) 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
WO2004004635A2 (en) 2002-07-02 2004-01-15 Board Of Regents, The University Of Texas System Radiolabeled compounds and liposomes and their methods of making and using the same
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
US20040203069A1 (en) * 2003-04-10 2004-10-14 Chris Reutelingsperger Method for determining and/or isolating lipid-binding compounds
WO2004098524A2 (en) * 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
US20060165744A1 (en) * 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
WO2005000272A1 (en) * 2003-06-04 2005-01-06 Isis Pharmaceuticals, Inc. Long-circulating liposomal compositions
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1547674A1 (en) 2003-12-23 2005-06-29 MediGene Oncology GmbH Method for producing colloidal nanoparticles
WO2005078139A2 (en) 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
ES2616047T3 (es) 2004-05-03 2017-06-09 Merrimack Pharmaceuticals, Inc. Liposomas útiles para la administración de fármacos
EP1795182A4 (en) 2004-08-31 2012-10-03 Astellas Pharma Inc LIPOSOME IMPROVING INTRACELLULAR DRUG DELIVERY
US20080014253A1 (en) 2004-11-03 2008-01-17 Kent Jorgensen Lipid-Based Drug Delivery Systems Containing Unnatural Phospholipase A2 Degradable Lipid Derivatives and the Therapeutic Uses Thereof
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20100189771A1 (en) 2005-10-25 2010-07-29 Lawrence Mayer Fixed ratio drug combination treatments for solid tumors
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
EP2487253B1 (en) 2006-01-05 2015-06-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
WO2007123691A2 (en) * 2006-03-30 2007-11-01 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
JP5248492B2 (ja) * 2006-07-14 2013-07-31 エフエムシー バイオポリマー エイエス 低分子量アルギネートを含むヒドロゲルおよびそれから製造されたバイオ構造物
US20080069778A1 (en) * 2006-09-20 2008-03-20 Imarx Therapeutics, Inc. Polymer-encapsulated microspheres
WO2009038779A2 (en) 2007-09-19 2009-03-26 University Of Tennessee Research Foundation Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Also Published As

Publication number Publication date
AU2009248673A1 (en) 2009-11-26
EP2299977A2 (en) 2011-03-30
CA2725529A1 (en) 2009-11-26
US20120009243A1 (en) 2012-01-12
CY1115325T1 (el) 2017-01-04
JP5767580B2 (ja) 2015-08-19
DK2299977T3 (da) 2012-11-05
JP2011521913A (ja) 2011-07-28
CA2725529C (en) 2016-07-05
CN102065840B (zh) 2014-12-10
EP2123258A1 (en) 2009-11-25
CN102065840A (zh) 2011-05-18
WO2009141450A2 (en) 2009-11-26
AU2009248673B2 (en) 2014-08-21
EP2299977B1 (en) 2012-08-15
US20200171080A1 (en) 2020-06-04
WO2009141450A3 (en) 2010-07-08
PT2299977E (pt) 2012-09-07
PL2299977T3 (pl) 2013-01-31
HRP20120776T1 (hr) 2012-10-31
ES2393170T3 (es) 2012-12-19
US11173178B2 (en) 2021-11-16

Similar Documents

Publication Publication Date Title
SI2299977T1 (sl) Liposomi za dostavo zdravil in postopki za njihovo pripravo
IL276157A (en) Pharmaceutical preparations and methods for transferring them related to them
IL207569A0 (en) Compositions and methods for drug delivery
IL216374A0 (en) Compositions and methods for drug delivery
ZA201101737B (en) Progestin-containing drug delivery system
IL210883A0 (en) Drug delivery system and method of munufacturing thereof
EP2600876A4 (en) METHODS AND APPARATUSES FOR COMBINED DRUG DELIVERY
IL215608A0 (en) Drug delivery composition
IL195764A0 (en) Compositions and methods for drug delivery
EP2299989A4 (en) STERILIZED TRANSDERMAL DRUG DELIVERY SYSTEM
EP2413917A4 (en) DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME
IL208390A0 (en) Permeant delivery system and methods for use thereof
IL212767A0 (en) Device and method for drug delivery
EP2420449A4 (en) MEDICAMENT DISPENSER AND MEDICAMENT DISTRIBUTION UNIT
SI2464342T1 (sl) Farmacevtske formulacije proti zlorabi zdravil
ZA201008589B (en) Medicament dispenser and method
IL212357A0 (en) Sustained drug delivery system
IL213577A0 (en) Drug delivery device
ZA201109514B (en) Method of drug delivery
GB201006818D0 (en) Drug delivery
IL212603A0 (en) Combined drug administration
ZA201006517B (en) Estradiol-containing drug delivery system
IL199865A0 (en) Methods of determining drug dose delivery
GB0716003D0 (en) Delivery of drug combinations
IL212150A0 (en) Protocol and methods for pulsating drug delivery